PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs: approval of nivolumab for unresectable advanced or recurrent epithelial skin malignancies in Japan
Crossref DOI link: https://doi.org/10.1007/s10147-024-02524-0
Published Online: 2024-04-16
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Matsumura, Noriomi
Mandai, Masaki
Text and Data Mining valid from 2024-04-16
Version of Record valid from 2024-04-16
Article History
First Online: 16 April 2024
Free to read: This content has been made available to all.